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AbstrACt
Introduction Cognitive training is an emerging non-
pharmacological treatment to improve cognitive and 
physical function in mild cognitive impairment (MCI) and 
early Alzheimer’s disease (AD). Abnormal brain blood flow 
is a key process in the development of cognitive decline. 
However, no studies have explored the effects of cognitive 
training on brain blood flow in dementia. The primary aim 
of this study is to assess the feasibility for a large-scale, 
randomised controlled trial of cognitive training in healthy 
older adults (HC), MCI and early AD.
Methods and analysis This study will recruit 60 
participants, in three subgroups of 20 (MCI, HC, AD), from 
primary, secondary and community services. Participants 
will be randomised to a 12-week computerised cognitive 
training programme (five × 30 min sessions per week), or 
waiting-list control. Participants will undergo baseline and 
follow-up assessments of: mood, cognition, quality of life 
and activities of daily living. Cerebral blood flow will be 
measured at rest and during task activation (pretraining 
and post-training) by bilateral transcranial Doppler 
ultrasonography, alongside heart rate (3-lead ECG), end-
tidal CO
2 (capnography) and beat-to-beat blood pressure 
(Finometer). Participants will be offered to join a focus 
group or semistructured interview to explore barriers and 
facilitators to cognitive training in patients with dementia. 
Qualitative data will be analysed using framework analysis, 
and data will be integrated using mixed methods matrices.
Ethics and dissemination Bradford Leeds Research 
Ethics committee awarded a favourable opinion (18/
YH/0396). Results of the study will be published in 
peer-reviewed journals, and presented at national and 
international conferences on ageing and dementia.
trials registration number NCT03656107; Pre-results.
IntroduCtIon
The incidence of dementia is rising as the 
population ages, with 46.8 million people 
living with dementia worldwide.1 2 By 2030, 
this is projected to rise to 75 million.1 2 
However, there are currently few diagnostic 
or therapeutic strategies available to offer 
these patients. Dementia is a progressive 
condition characterised by gradual loss of 
cognitive and/or non-cognitive higher func-
tions (ie, language, visuospatial, attention).3 
Mild cognitive impairment (MCI) is charac-
terised by subjective and objective decline 
in cognitive function, but with preserved 
functional independence in daily living.4 
It has become increasingly recognised that 
deranged vascular function is an early contrib-
utor to the deposition of amyloid plaques 
and tau tangles in Alzheimer’s disease (AD), 
and that these pathologies exacerbate one 
another (two-hit hypothesis).5 In a recent 
systematic review and meta-analysis, we 
demonstrated clear abnormalities in vascular 
function across a number of imaging modal-
ities at the MCI stage.6 Thus, treatments that 
can improve cerebral perfusion or vascular 
function could represent an early treatment 
option for dementia.6 In this study, the target 
strengths and limitations of this study
 ► This study uses a mixed methods approach to in-
vestigate the feasibility of cognitive training in 
healthy older adults, mild cognitive impairment and 
Alzheimer’s disease.
 ► This study includes an assessment of the effects 
of cognitive training on neurovascular function, by 
transcranial Doppler ultrasonography.
 ► This study includes a broad range of outcome mea-
sures to take a holistic approach to evaluating cog-
nitive training in dementia.
 ► The primary aim of this study is to identify the fea-
sibility of this protocol in patients with cognitive im-
pairment, and as such is not a fully powered trial.
 ► This study is limited to identifying these outcomes in 
healthy older adults, mild cognitive impairment and 
Alzheimer’s disease with mild-to-moderate deficits.
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populations are: healthy older adults (as controls), adults 
with AD and MCI, to capture the effects of cognitive 
training on vascular physiology at an early stage in the 
dementia process.
The Cognition and Flow Study (CogFlowS) is a feasi-
bility, parallel, randomised controlled trial (RCT) to 
examine the use of a cognitive training programme 
in adults with MCI, early AD and healthy older adults 
(HC). In addition to measuring cognitive and functional 
outcomes, this study will also use transcranial Doppler 
ultrasonography (TCD) to measure changes in cerebral 
blood flow (CBF) before and after a 12-week cognitive 
training programme.
Cognitive interventions can be considered as three 
broad categories: cognitive training, cognitive rehabil-
itation and cognitive stimulation.7 8 Cognitive training 
describes a structured, guided programme of stan-
dardised tasks designed to provide practice or training 
within a specified cognitive domain(s), to translate into 
functional benefits.7 8 This is distinguished from cogni-
tive rehabilitation, where patient-centred approaches and 
goals are used to improve everyday function, rather than 
improve cognition function,7–9 and cognitive stimulation 
which aims to generally improve cognition, social func-
tion and quality of life.10 Cognitive training is attractive 
in that it offers a cost-effective, non-invasive and accept-
able intervention to patients, with no reported adverse 
effects.11 However, high-quality RCT evidence is lacking 
in studies of cognitive training in dementia.8 9 12 13 Two 
previous Cochrane reviews8 9 highlighted that the 
evidence was sparse, with many of the studies underpow-
ered, of low-to-moderate quality and with relatively few 
for MCI.8 9 Recent systematic reviews of cognitive training 
in MCI have demonstrated moderate benefits in verbal 
learning and memory, global cognition, non-verbal 
learning, working memory, attention and psychosocial 
functioning.12 14 Thus far, studies of cognitive training 
in dementia have been heterogeneous in study design, 
participants included, type and definition of training, 
outcome measures and duration and intensity of inter-
vention.8 9 13 15 16 This hampers the adequate meta-anal-
ysis of data, and of conclusions that can be drawn from 
pooled analyses.13 17 Few studies have included neuro-
imaging outcomes to explore brain plasticity or neural 
mechanisms underlying changes in cognition after cogni-
tive training.17 Therefore, the CogFlowS addresses the 
development of a future high-quality RCT of cognitive 
training in dementia, and aims to fill the evidence gap on 
the use of TCD to assess neurovascular plasticity.
TCD is a non-invasive, ultrasound-based imaging 
modality that allows measurements of CBF velocity (CBFv) 
at rest18 and following activation by cognitive tasks.19 TCD 
has a number of advantages over other functional imaging 
techniques, such as: MRI and positron emission tomog-
raphy (PET), including lower cost, portability, relative 
ease of operator training, high temporal resolution and 
higher acceptability to patients.20 21 TCD is particularly 
suited to older people, and those with dementia, as it can 
be used in patients with pacemakers, metal implants and 
claustrophobia.20 The use of TCD is a novel method to 
investigate neurovascular training effects and for markers 
predictive of which patients may benefit from particular 
cognitive training programmes. This would allow the 
development of a personalised approach to developing 
cognitive training programmes for people with dementia.
The use of neuroimaging outcomes has also been 
limited in cognitive training studies,17 22 but understanding 
the training effects occurring at the physiological level 
may provide important mechanistic information to any 
potential benefits conferred by cognitive training.23–25 
Belleville et al demonstrated increased parietal activa-
tion in patients with MCI, following a multimodal cogni-
tive training programme designed to improve episodic 
memory.23 In a near-infrared spectroscopy study by Vermeij 
et al, patients with MCI had greater training benefits at 
high load working memory where participants had greater 
prefrontal activation,26 whereas baseline global and hippo-
campal atrophy were predictive of poorer training gains 
in healthy older adults and those with MCI.24 Therefore, 
imaging biomarkers can potentially be used to predict and 
tailor interventions to individual patient’s needs.24 25 While 
a number of studies have demonstrated positive structural 
and functional effects of cognitive training,25 27 28 they have 
largely focused on healthy older adults,27 with the use of 
structural27 or functional MRI23 24 and PET29 30; there have 
been no TCD studies examining changes in neurovascular 
response to cognitive training in patients with cognitive 
impairment. In addition to the inclusion of neuroimaging, 
this study uses a mixed methods approach. This study 
includes a qualitative component to explore any bene-
fits, problems or barriers to engaging with the training 
programme, and to identify any benefits not measured by 
traditional outcomes.
The primary objective for this study is to determine the 
feasibility for a large-scale RCT of cognitive training in 
HC, AD and MCI. Secondary objectives seek to identify 
any clinical benefits of a cognitive training programme in 
terms of: activities of daily living, cognition, mood, quality 
of life and TCD-measured task activation responses in 
brain blood flow. In addition, the qualitative study seeks to 
explore barriers and facilitators to the cognitive training 
programme, how programmes can be adapted to support 
participation for patients living with dementia and any 
additional benefits not measured through traditional 
methods as perceived by patients and their carers. Finally, 
we plan to explore the lived experience of the patient and 
their carer, and the impact cognitive training has on them 
and their life.
MEthods And AnAlysIs
This protocol was reported in accordance with the 
Standard Protocol Items: Recommendations for Inter-
ventional Trials checklist,31 which is included in online 
supplementary information.
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Patient and public involvement
During the design phase of this study, a patient and public 
involvement (PPI) group was consulted, comprised 
research network volunteers from the Alzheimer’s society 
who were either people living with cognitive impairment 
or their carers. The group reviewed the study design, 
research questions and outcome measures, and a number 
of changes were made as a result. These included: 
providing an option of a focus group or interview to 
participants, changes to the recruitment procedures 
and the design of the cognitive training programme. All 
study participants will receive a lay summary at the end 
of the study explaining what the outcomes of the study 
were. A further PPI meeting was held following successful 
funding to refine the study documentation and proce-
dures for participants. The trial will be overseen by a 
trial steering committee (TSC), consisting of patient and 
public members, and independent academics. The TSC 
will review the trial conduct on a six monthly basis. As this 
is a feasibility trial, the burden of intervention is to be 
assessed in terms of its acceptability to patients and their 
carers.
sample selection
HC will be recruited through poster advertisement, 
friends, family and carers of enrolled patient participants, 
Join Dementia Research and the research interested list 
at the University of Leicester. Participants with a diagnosis 
of MCI, or AD, will be recruited through poster adver-
tisement, secondary care services (outpatient clinics 
within the University Hospitals of Leicester (acute) and 
the Leicestershire Partnership (mental health) National 
Health Service Trusts), research interested lists, Join 
Dementia Research and local community groups. In 
addition, participants will be sought through letter invita-
tion from their general practitioner (GP) surgery. Partic-
ipants will be allowed a minimum of 24 hours to decide if 
they would like to enrol in the study, and to contact the 
researcher or research delivery team at the Leicestershire 
Partnership Trust, who will arrange for them to undergo 
an eligibility assessment, formal consent and study enrol-
ment. As part of the eligibility assessment, participants 
will undergo a screening cognitive assessment (Montreal 
Cognitive Assessment—MoCA) to ensure deficits are clas-
sified as mild to moderate. Participants will be consented 
for this, and the MoCA will not form part of the base-
line assessments. For participants who lack capacity to 
consent to the study, a personal consultee declaration will 
be completed by a friend, relative or carer, in addition 
to verbal assent from the participant themselves where 
possible. Flow charts of the recruitment process and 
participant procedures can be seen in figures 1 and 2, 
respectively.
The planned recruitment target for this study is 60 
participants, divided into three subgroups of 20 (HC, AD 
Figure 1 Flow chart of study recruitment procedures. LPT, Leicestershire Partnership Trust; MoCA, Montreal Cognitive 
Assessment; UHL, University Hospitals of Leicester.
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and MCI). As the primary aim of this study is feasibility, a 
formal sample size calculation has not been performed. 
Recruiting between 24 and 50 participants for a feasibility 
study is acceptable and therefore the planned target of 
60 participants is sufficiently large enough while giving a 
margin for drop-outs and loss to follow-up.32 33
The following inclusion and exclusion criteria were 
designed to identify a sample of participants that will 
be able to engage with a cognitive training programme, 
and to exclude any major medical comorbidities that can 
affect CBF:
Inclusion criteria
1. Healthy controls will be free of any medical comorbid-
ity or medication that could adversely affect cognition. 
Volunteers with well-controlled comorbidities (ie, hy-
pertension, diabetes, will be considered for inclusion).
2. MCI as defined by NIA/AA 201134 and Petersen crite-
ria.4
3. AD as defined by the NIA/AA 2011 criteria.34
And:
4. Deficits will be mild to moderate as defined by MoCA 
score of >9 for participants with MCI and AD.35–37
5. Willing to participate.
6. Capacity to consent to the study/personal consultee.
7. Patients on and off antidementia medications will be 
included (acetylcholinesterase inhibitors, glutamate 
receptor antagonists).
8. Good understanding of written and spoken English.
9. Age>50 years.
10. Access to the internet and a computer/laptop device.
Exclusion criteria
1. Healthy controls with any medical comorbidity or 
medication that could adversely affect cognition, or 
poorly controlled medical comorbidities (ie, hyper-
tension, diabetes).
2. Unwilling to take part.
3. Unable to consent/no personal consultee.
4. Major medical comorbidity: severe heart failure 
(ejection fraction <20%), carotid artery stenosis, se-
vere respiratory disease, major stroke.
5. Pregnancy, planning pregnancy or lactating.
6. Inadequate bilateral TCD windows.
7. Participants already enrolled into other intervention-
al studies that would confound study results
8. Insufficient understanding of written and spoken 
English.
9. Age<50 years.
10. No access to the internet and a computer/laptop 
device.
Intervention
Participants randomised to the intervention will complete 
a 12-week cognitive training programme. Participants will 
be required to complete five, 30 min sessions per week 
for 12 weeks. The cognitive training programme will be 
provided by Lumosity as part of a collaboration through Figure 2 Flow chart of participant procedures during the 
study.
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the Human Cognition Project. Lumosity is commercially 
available software, developed by a group of neuropsy-
chologists, which has been used across several studies 
of brain training and disciplines.38–40 These studies 
have been included in a number of systematic reviews 
and meta-analysis.12 41 It is a multidomain, online-based 
cognitive training tool, which is relatively easy to use and 
administer. It has been designed to adapt to the individu-
al’s cognitive function in order to administer the training 
programme to their individual level of cognitive function. 
Exercises will be selected from Lumosity’s commercially 
available online software which have been preclassi-
fied to target the following cognitive domains: atten-
tion, memory, visuospatial, verbal fluency and language. 
These five cognitive domains will be evaluated through 
formal cognitive testing, and through the neurovascular 
coupling assessment. Compliance will be monitored 
through Lumosity online software which will log and 
track the number of minutes and times per week a partic-
ipant has spent training, in order to calculate the dose of 
training to which each participant has been exposed.
randomisation
Randomisation will be performed using Sealed Envelope, 
by the researcher. This is an online-based randomisation 
tool which uses random permuted blocks to allocate 
participants to waiting list control or intervention. Partic-
ipants will be enrolled and assigned a patient identiica-
tion number (PIN) consecutively, and randomised to 
a treatment arm corresponding to the PIN. Given the 
nature of the trial, it is not possible to blind participants 
to the intervention. The investigator will be providing 
weekly telephone support for the intervention group, in 
addition to undertaking baseline and follow-up measure-
ments, and therefore blinding of the investigator is also 
not possible. However, data analysis will be blinded by 
generating a batch-anonymised dataset. Randomisation 
will be undertaken at the initial visit. Once participants 
have been randomised to the intervention arm, they will 
be provided with information on how to access and use 
the cognitive training programme at home.
data collection and integration
All participants (intervention and control groups) will be 
required to attend two assessments: baseline and follow-up 
at 12-weeks post training. Assessments will be carried out 
at the participant’s home, or designated research space at 
the Leicestershire Partnership Trust, or Cerebral Haemo-
dynamics in Ageing and Stroke Medicine (CHiASM) 
research space. Participants will be given the option to 
divide the assessments across two visits if necessary. This 
is to reduce any burden of participation for people living 
with dementia, who may fatigue more quickly with the 
baseline and follow-up assessments. It is anticipated that 
the majority of participants will be able to complete all 
assessments in one visit, and this will be included within 
the feasibility assessment for the study.
Data will be collected on demographics, medical 
history and medication use. Assessments of cognition 
(Addenbrooke’s Cognitive Examination III (ACE-III)), 
mood (Geriatric Depression Scale 15), activities of daily 
living (Lawton instrumental activities of daily living) and 
quality of life (Dementia Rated Quality of Life) will be 
carried out at both visits. An assessment of neurovascular 
function will be carried out at the CHiASM research 
space, a temperature-controlled room, free of noise and 
distraction. Participants will be seated throughout the 
protocol. All measurements will be made at rest (5 min 
baseline recording), and during cerebral activation 
(selected cognitive tasks). CBFv will be measured contin-
uously by insonation of the bilateral middle cerebral 
arteries (MCA) (DWL Doppler Box), using 2 MHz probes, 
fixed in place with a headframe. Beat-to-beat blood pres-
sure (BP) will be measured continuously using a Finom-
eter cuff on the non-dominant middle finger (Finapres 
Medical Systems, Amsterdam, The Netherlands), and 
calibrated using a brachial BP recording (UA767 BP 
monitor). End-tidal CO2(ETCO2) will be measured by 
capnography using nasal cannulae (Capnochek Plus), 
and the R-R interval will be recorded using a 3-lead ECG. 
The task activation protocol has been published previ-
ously.42 43 In brief, participants will be presented with five 
tasks selected from the ACE-III, and percentage increase 
in CBFv from resting baseline will be calculated at task 
initiation. The tasks will be selected for five cognitive 
domains: attention, memory, visuospatial, language and 
verbal fluency, based on recent studies conducted by this 
group.43 44 Data will be collected on the following param-
eters: average CBFv, ETCO2, HR and BP at rest over 
5 min, and peak percentage change from baseline in all 
parameters at 5–10 s, and 10–20 s after task activation for 
each of the five cognitive tasks.
At least 1 week after completion of the follow-up assess-
ment, participants with a diagnosis of MCI, or AD, will 
be invited to attend a semistructured interview or focus 
group. The schedule of questions can be seen in online 
supplementary information. The schedule of questions 
has been framed around the six constructs of the health 
belief model (risk susceptibility, risk severity, benefits to 
action, barriers to action, self-efficacy and cues to action)45 
to evaluate the cognitive training programme, and the 
experience of the participant and their carer. Interviews 
and focus groups will be recorded continuously with a 
digital audio recorder, and notes of non-verbal and para-
linguistic clues will be made. All digital recordings will 
be transcribed within 5–7 days of the interview or focus 
group. Semistructured interviews are an iterative process, 
following the first couple of interviews the transcripts will 
be analysed and the themes and concepts emerging from 
these initial data will be further explored at the following 
interviews.
Data security and storage will be conducted in line with 
general data protection regulations (https:// eugdpr. 
org/), and details regarding data security and storage can 
be seen in online supplementary information.
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trial discontinuation
This is not a drug intervention trial, and therefore interim 
analysis will not be required. Criteria for trial discontinu-
ation are as follows: ineligibility, significant protocol devi-
ation, significant non-adherence to the programme, an 
adverse event or disease progression resulting in inability 
to comply with study procedures, consent withdrawn or 
lost to follow-up.
data analysis and interpretation
The difference for each participant between baseline and 
follow-up assessment for each of the continuous outcome 
measures described above will be reported along with the 
overall mean difference.
CBFv data will be recorded and stored in the PHYSIDAS 
system, and analysed offline. Data will be visually inspected 
for quality, and files rejected where quality is deemed to 
be poor, with reasons. Peak percentage change in CBFv 
will be calculated relative to a 20 s baseline, prior to task 
initiation.
The findings from the semistructured interviews and 
focus groups will be evaluated using framework analysis.41 
The digital recordings of the interviews and focus groups 
will be transcribed verbatim, the transcripts will be read in 
detail, that is, line by line, and open codes will be formed 
categorising and conceptualising the responses and iden-
tifying the major themes. Two researchers LB and RE will 
independently code the first few transcripts to ensure 
consistency in coding.
Following this initial coding, the analytical framework 
will be developed; this is an iterative process and will 
develop through coding of additional transcripts. Once 
the final transcript has been coded, the analytic frame-
work will be used to generate the framework matrix. The 
framework matrix will be developed in NVivo V.11 (QSR 
International), and allow for the recognition of patterns 
and outliers within the data. Respondent validation will be 
used to establish a degree of correspondence between the 
researcher’s views and those of the research participant.46
Data from the quantitative and qualitative arms of the 
study will be integrated using mixed methods approaches 
of triangulation and mixed methods matrices.47
statistical analysis and sample size calculation
Data will be checked for normality, and non-normally 
distributed data will be appropriately transformed, and 
parametric tests applied. Data will be reported as mean 
(SD) for continuous variables, and number (percentage) 
for nominal data. Differences in baseline demographics 
between the intervention and control groups will be anal-
ysed within population group (HC/AD/MCI) using Χ2 
for nominal data, and independent t-testing for contin-
uous data. Any baseline differences in demographics 
between population groups will also be reported. To assess 
the impact of the intervention and population group on 
each of these differences, a two-way analysis of variance 
will be carried out. The interaction between population 
group and treatment group will be analysed to assess if 
the difference between the treatment groups is different 
between the population groups. Post-hoc testing will be 
conducted by Tukey to analyse for main effects. Data will 
be recorded in Microsoft Excel. Statistical analyses will be 
performed using the latest version of SPSS for Windows 
(SPSS V.24), and graphs will be produced using the latest 
version of GraphPad Prism for Windows.
study limitations
This is a feasibility study, and thus will not be powered 
adequately to detect changes in the secondary end points 
outlined above. However, given the novel aspects of this 
study protocol, such as the inclusion of a TCD-measured 
changes in CBF responses, and the mixed methods 
design, this requires evaluation of the feasibility before 
moving to a larger, fully powered trial of cognitive training 
in dementia. Furthermore, this study will include assess-
ments of patient experience and tolerability to facilitate 
this. Although TCD affords excellent temporal resolution 
in the measurement of CBFv, the MCA supplies blood 
to approximately 80% of the cerebral cortex, and there-
fore reflects a global measure of perfusion, and cannot 
discriminate where changes are occurring, due to poor 
spatial resolution. Techniques such as MRI, and PET scans 
afford better spatial resolution, but have their own limita-
tions, particularly in older patients with cognitive deficits. 
TCD-measured CBFv relies on the assumption that the 
vessel diameter remains constant, despite fluctuations in 
CO2 and BP.
18 This study elected to focus on healthy older 
adults, MCI and AD in the first instance. Deficits in CBFv 
have been demonstrated in both MCI and AD, but inclu-
sion of participants with vascular cognitive impairment 
would provide further information on the capacity for 
plasticity to neurovascular physiology among dementia 
subtypes. In addition, only participants with mild-to-
moderate deficits will be included, given that data thus 
far do not support the use of cognitive training in more 
advanced dementia.9 12 Only participants who are under-
taking the training programme will be offered telephone 
support, as it is primarily to support technical issues with 
delivery of the programme. However, this could intro-
duce a placebo effect, and future studies would ideally 
correct for this by providing support to both groups. 
Finally, one investigator is undertaking both baseline and 
follow-up assessments, and providing telephone support, 
which carries a risk of introducing researcher bias into 
the study. As this is primarily a feasibility study, this is of 
lesser importance here, but a future trial should ideally 
have separate team members conducting these different 
roles to minimise the risk of bias.
EthICs And dIssEMInAtIon
safety considerations
All participants with capacity in this study will provide 
informed, written consent, and the study will be conducted 
in accordance with the Declaration of Helsinki and 
Good Medical Practice guidelines.48 Given the nature of 
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dementia, not all participants will have capacity to consent 
to the study. In this instance, a personal consultee (friend, 
relative or carer) will be consulted for their opinion on 
whether the participant is likely to have wanted to partici-
pate in this study, and they will be asked to sign a consultee 
declaration form. It was not considered ethical to exclude 
participants on the grounds of capacity, given the nature 
of the disease studied.
dissemination
The results from this study will be submitted to peer-re-
viewed journals in ageing and dementia research, and 
presented at national and international conferences 
on these themes. We anticipate that the results will be 
presented and published in late 2020, early 2021. In addi-
tion, the results will be disseminated to members of the 
community through the Alzheimer’s Society, community 
groups, podcasts and social media.
trial committees and monitoring
The study will be monitored at six monthly intervals 
throughout its duration by a TSC, independent of the 
funder, consisting of lay and independent academic 
members. Each site will have a lead investigator who is 
responsible for the identification and recruitment of 
participants, data collection and completion for CRFs, 
follow-up measurements and adherence to study proto-
cols. Serious adverse events (SAEs) will be reported to 
the sponsor within one working day of identification, and 
the sponsor will report all serious unexpected or adverse 
reactions to the ethics committee concerned. The chief 
investigator will submit an annual report to the ethics 
committee which lists all SAEs. Where necessary, protocol 
amendments will be submitted to the study sponsor or 
ethics committee for approval.
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